Collegium Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Collegium Pharmaceutical
COLL Stock  USD 45.91  0.01  0.02%   
Collegium Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Collegium Pharmaceutical's valuation are provided below:
Gross Profit
667.5 M
Profit Margin
0.0772
Market Capitalization
1.5 B
Enterprise Value Revenue
2.5912
Revenue
757.1 M
There are over one hundred nineteen available fundamental signals for Collegium Pharmaceutical, which can be analyzed over time and compared to other ratios. We recommend to validate Collegium Pharmaceutical's prevailing fundamental drivers against the all of the trends between 2010 and 2026. Enterprise Value is expected to rise to about 1.6 B this year, although the value of Market Cap will most likely fall to about 454.3 M.

Collegium Pharmaceutical Total Revenue

762.47 Million

Check Collegium Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Collegium Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 204.3 M, Interest Expense of 89.3 M or Selling General Administrative of 105.2 M, as well as many indicators such as Price To Sales Ratio of 1.6, Dividend Yield of 0.0721 or PTB Ratio of 5.12. Collegium financial statements analysis is a perfect complement when working with Collegium Pharmaceutical Valuation or Volatility modules.
  
Build AI portfolio with Collegium Stock
Check out the analysis of Collegium Pharmaceutical Correlation against competitors.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.

Collegium Pharmaceutical Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2 B1.9 B604.3 M
Slightly volatile
Short and Long Term Debt Total1 B988.2 M285.7 M
Slightly volatile
Total Current Liabilities615.2 M585.9 M211.3 M
Slightly volatile
Other Liabilities816.3 K777.4 K469.5 K
Slightly volatile
Property Plant And Equipment Net14.5 M23.2 M11.6 M
Slightly volatile
Accounts Payable7.5 M4.5 M5.7 M
Slightly volatile
Cash140.9 M81.1 M104.8 M
Slightly volatile
Non Current Assets Total1.4 B1.4 B363.7 M
Slightly volatile
Non Currrent Assets Other11.4 M10.8 M2.5 M
Slightly volatile
Other Assets21.1 M22.2 M61.5 M
Pretty Stable
Cash And Short Term Investments155.9 M187.2 M121.6 M
Slightly volatile
Common Stock Total Equity29.4 K42.5 K24.5 K
Slightly volatile
Common Stock Shares Outstanding31.3 M46.5 M26 M
Slightly volatile
Liabilities And Stockholders Equity2 B1.9 B604.3 M
Slightly volatile
Non Current Liabilities Total1.1 B1.1 B272.2 M
Slightly volatile
Other Current Assets66.9 M63.7 M13.6 M
Slightly volatile
Other Stockholder Equity371.9 M451.7 M289.3 M
Slightly volatile
Total Liabilities1.7 B1.6 B483.1 M
Slightly volatile
Property Plant And Equipment Gross40.7 M38.7 M15.5 M
Slightly volatile
Total Current Assets582.3 M554.6 M240.6 M
Slightly volatile
Short Term Debt48.6 M75.7 M38.6 M
Slightly volatile
Common Stock31.6 K46 K25 K
Slightly volatile
Property Plant Equipment23.6 M22.4 M10.6 M
Slightly volatile
Net Receivables276 M262.8 M88 M
Slightly volatile
Short and Long Term Debt52 M74.3 M38.3 M
Slightly volatile
Long Term Debt Total650.2 M619.2 M197.1 M
Slightly volatile
Capital Surpluse468.8 M618.8 M390.8 M
Slightly volatile
Capital Lease Obligations7.9 M7.8 M5.1 M
Slightly volatile
Non Current Liabilities Other1.3 M1.4 M2.3 M
Slightly volatile
Net Invested Capital1.3 B1.2 B419.3 M
Slightly volatile
Capital Stock39.8 K46 K35.5 K
Slightly volatile

Collegium Pharmaceutical Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization204.3 M194.5 M65.6 M
Slightly volatile
Interest Expense89.3 M85.1 M27.5 M
Slightly volatile
Selling General Administrative105.2 M198.2 M85.7 M
Slightly volatile
Other Operating Expenses557.3 M530.8 M224.9 M
Slightly volatile
Total Operating Expenses120.9 M238.6 M101.6 M
Slightly volatile
Interest Income16.9 M16.1 M4 M
Slightly volatile
Selling And Marketing Expenses9.1 M9.6 M56.4 M
Slightly volatile
Reconciled Depreciation98.3 M194.5 M59.5 M
Slightly volatile
Non Recurring3.7 M4.1 M4.5 M
Slightly volatile

Collegium Pharmaceutical Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation39.1 M37.3 M14.8 M
Slightly volatile
Begin Period Cash Flow289.8 M276 M122.9 M
Slightly volatile
Depreciation204.3 M194.5 M65.6 M
Slightly volatile
Capital Expenditures1.8 M1.9 M24.7 M
Pretty Stable
End Period Cash Flow144.1 M111.1 M108.8 M
Slightly volatile
Dividends Paid10.5 M8.2 M14.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.61.6893.0789
Slightly volatile
Dividend Yield0.07210.07480.0664
Slightly volatile
Days Sales Outstanding171152262
Slightly volatile
Stock Based Compensation To Revenue0.05610.0591.4401
Slightly volatile
Capex To Depreciation0.01070.01121.1782
Pretty Stable
EV To Sales2.963.1257.2862
Slightly volatile
Inventory Turnover6.986.435.4651
Slightly volatile
Days Of Inventory On Hand55.858.74968
Slightly volatile
Payables Turnover61.0458.1321.9299
Slightly volatile
Sales General And Administrative To Revenue0.220.250.2684
Slightly volatile
Research And Ddevelopement To Revenue0.00940.00993.6254
Slightly volatile
Capex To Revenue0.00290.0030.797
Slightly volatile
Cash Per Share3.864.544.0756
Slightly volatile
Days Payables Outstanding6.176.53.6 K
Slightly volatile
Intangibles To Total Assets0.290.570.234
Slightly volatile
Current Ratio1.031.093.0027
Slightly volatile
Receivables Turnover2.322.492.1028
Slightly volatile
Graham Number11.6416.6411.6108
Slightly volatile
Capex Per Share0.04380.04610.7263
Pretty Stable
Revenue Per Share18.4917.617.1731
Slightly volatile
Interest Debt Per Share27.3326.038.7581
Slightly volatile
Debt To Assets0.50.590.3994
Pretty Stable
Operating Cycle2002111.2 K
Slightly volatile
Days Of Payables Outstanding6.176.53.6 K
Slightly volatile
Total Debt To Capitalization0.860.911.3689
Pretty Stable
Quick Ratio0.961.012.9598
Slightly volatile
Cash Ratio0.150.162.5374
Slightly volatile
Days Of Inventory Outstanding55.858.74968
Slightly volatile
Days Of Sales Outstanding171152262
Slightly volatile
Fixed Asset Turnover29.6128.213.2689
Slightly volatile
Debt Ratio0.50.590.3994
Pretty Stable
Price Sales Ratio1.61.6893.0789
Slightly volatile
Asset Turnover0.380.340.2993
Slightly volatile
Gross Profit Margin0.650.690.699
Slightly volatile

Collegium Pharmaceutical Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap454.3 M832.2 M509.2 M
Slightly volatile
Enterprise Value1.6 B1.5 B684.8 M
Slightly volatile

Collegium Fundamental Market Drivers

Forward Price Earnings6.105
Cash And Short Term Investments162.8 M

Collegium Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Collegium Pharmaceutical Financial Statements

Collegium Pharmaceutical investors utilize fundamental indicators, such as revenue or net income, to predict how Collegium Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue11.5 M12.1 M
Total Revenue726.2 M762.5 M
Cost Of Revenue292.2 M306.8 M
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 0.25  0.22 
Research And Ddevelopement To Revenue 0.01  0.01 
Revenue Per Share 17.61  18.49 
Ebit Per Revenue 0.24  0.25 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:
How To Invest In Collegium
Details
Is Collegium Stock a good investment?
Details
What is Collegium Pharmaceutical's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Collegium Pharmaceutical Correlation against competitors.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. Projected growth potential of Collegium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Collegium Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
2.132
Earnings Share
1.65
Revenue Per Share
23.798
Quarterly Revenue Growth
0.314
Return On Assets
0.0675
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY